GlassScriptPhysician profile
Jordan Willis
NPI 1982330411
$8,955.87
in general payments reported to CMS, 2019-2025
23 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,456 · 2023: $4,823 · 2024: $2,469 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,211 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,211.43 |
| Education | $288.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,284.00 | 2022-2024 | |
| Lilly USA, LLC | $967.56 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $811.43 | 2022-2024 | Dupixent, Libtayo |
| Genzyme Corporation | $683.09 | 2022-2024 | |
| Amgen INC. | $664.51 | 2023-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $628.89 | 2022-2024 | |
| Janssen Biotech, INC. | $525.47 | 2022-2025 | Tremfya |
| Pfizer INC. | $512.05 | 2022-2023 | |
| Dermavant Sciences, INC. | $488.04 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $423.88 | 2022-2024 | Sotyktu |
| Incyte Corporation | $396.62 | 2022-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $322.81 | 2022-2024 | Winlevi, Absorica Ld, Ilumya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.89 | 2022-2024 | Spevigo, Cyltezo |
| Ucb, INC. | $276.28 | 2022-2024 | Cimzia, Bimzelx |
| Arcutis Biotherapeutics, INC. | $198.11 | 2023-2025 | Zoryve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $135.43 | 2023-2024 | Idacio |
| Genentech USA, INC. | $106.82 | 2023-2024 | Erivedge |
| Leo Pharma INC. | $104.93 | 2023-2024 | Adbry |
| Galderma Laboratories, L.P. | $43.36 | 2023 | |
| Blueprint Medicines Corporation | $29.60 | 2023 | |
| Revance Therapeutics, INC. | $28.25 | 2025 | Daxxify |
| Krystal Biotech INC | $15.63 | 2023 | Vyjuvek |
| Organon LLC | $14.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.